Citation Impact
Citing Papers
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective
2023 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
2015
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Breast cancer
2019 Standout
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
2012
Ancient Fennoscandian genomes reveal origin and spread of Siberian ancestry in Europe
2018 StandoutNobel
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Breast cancer
2016 Standout
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study
2017
Delivery technologies for cancer immunotherapy
2019 Standout
Next-generation regulatory T cell therapy
2019
Drug repurposing: progress, challenges and recommendations
2018 Standout
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Artificial intelligence in drug development: present status and future prospects
2018 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
Diagnosing the decline in pharmaceutical R&D efficiency
2012 Standout
Monoclonal antibodies in myeloma.
2015
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
2022 StandoutNobel
Subtyping of triple‐negative breast cancer: Implications for therapy
2014
Taking regulatory T cells into medicine
2021 StandoutNobel
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
2017
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
2014
Fine-Scale Genetic Structure in Finland
2017
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design
2017
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
2020
American Trip
2020 Standout
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Éric Charpentier being referenced
Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/− Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice
2018
Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells
2017
Fine-scale human genetic structure in Western France
2014
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
2016
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
2011
SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).
2012
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2014
A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.
2014
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
2017
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
2014